NCT00595868View on ClinicalTrials.gov

Efficacy of Varenicline in Ambivalent Smokers

PHASE2CompletedINTERVENTIONAL
Enrollment

220

Participants

Timeline

Start Date

March 31, 2008

Primary Completion Date

January 31, 2010

Study Completion Date

January 31, 2010

Conditions
Tobacco Use DisorderTobacco Use CessationNicotine Dependence
Interventions
DRUG

Varenicline

0.5 milligrams two times per day for 3 days, then 1.0 milligrams two times per day for an addition 11 days - 2 months

DRUG

Placebo

same as Varenicline arm

Trial Locations (2)

68198

Nebraska Medical Center, Omaha

05401

University of Vermont, Burlington

Sponsors

Collaborators (1)

Pfizer
All Listed Sponsors
collaborator

Pfizer

INDUSTRY

lead

University of Vermont Medical Center

OTHER

NCT00595868 - Efficacy of Varenicline in Ambivalent Smokers | Biotech Hunter | Biotech Hunter